Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


PLEKHA5 regulates tumor growth in metastatic melanoma.

Zhang H, Zhu H, Deng G, Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg MW, Kluger HM, Jilaveanu LB.

Cancer. 2020 Mar 1;126(5):1016-1030. doi: 10.1002/cncr.32611. Epub 2019 Nov 26.


Complications associated with immunotherapy for brain metastases.

Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM.

Curr Opin Neurol. 2019 Dec;32(6):907-916. doi: 10.1097/WCO.0000000000000756.


Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy.

Tran TT, Mahajan A, Chiang VL, Goldberg SB, Nguyen DX, Jilaveanu LB, Kluger HM.

J Immunother Cancer. 2019 Jul 30;7(1):200. doi: 10.1186/s40425-019-0684-z.


Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB.

J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8.


On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies.

Calinescu A, Turcu G, Nedelcu RI, Brinzea A, Hodorogea A, Antohe M, Diaconu C, Bleotu C, Pirici D, Jilaveanu LB, Ion DA, Badarau IA.

J Immunol Res. 2018 Oct 14;2018:7169081. doi: 10.1155/2018/7169081. eCollection 2018. Review.


Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM.

Clin Cancer Res. 2018 Jan 1;24(1):217-223. doi: 10.1158/1078-0432.CCR-17-1555. Epub 2017 Oct 24.


PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.

Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB.

Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21.


Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.


CEACAM1: Expression and Role in Melanocyte Transformation.

Turcu G, Nedelcu RI, Ion DA, Brînzea A, Cioplea MD, Jilaveanu LB, Zurac SA.

Dis Markers. 2016;2016:9406319. doi: 10.1155/2016/9406319. Epub 2016 Aug 24. Review.


MET Inhibition in Clear Cell Renal Cell Carcinoma.

Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B.

J Cancer. 2016 Jun 18;7(10):1205-14. doi: 10.7150/jca.14604. eCollection 2016.


Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.

Rutter CE, Johung KL, Yao X, Lu AY, Jilaveanu LB, Yu JB, Contessa JN, Kluger HM, Chiang VLS, Bindra RS.

J Radiosurg SBRT. 2016;4(2):97-106.


Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, Chiang VL, Kluger HM.

Cancer Immunol Res. 2016 Mar;4(3):179-82. doi: 10.1158/2326-6066.CIR-15-0160. Epub 2015 Dec 23.


MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.

Shuch B, Falbo R, Parisi F, Adeniran A, Kluger Y, Kluger HM, Jilaveanu LB.

Biomed Res Int. 2015;2015:192406. doi: 10.1155/2015/192406. Epub 2015 Sep 13.


Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.

Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB.

Oncotarget. 2015 Sep 22;6(28):24990-5002. doi: 10.18632/oncotarget.4572.


Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB.

Clin Cancer Res. 2015 Jul 1;21(13):3052-60. doi: 10.1158/1078-0432.CCR-14-3073. Epub 2015 Mar 18.


PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.


PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B.

J Clin Pathol. 2015 Jan;68(1):12-7. doi: 10.1136/jclinpath-2014-202259. Epub 2014 Oct 14.


NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.

Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM.

Oncotarget. 2014 Jul 30;5(14):5209-17.


MEK targeting in N-RAS mutated metastatic melanoma.

Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM.

Mol Cancer. 2014 Mar 4;13:45. doi: 10.1186/1476-4598-13-45.


PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.

Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM.

J Cancer. 2014 Jan 24;5(3):166-72. doi: 10.7150/jca.8167. eCollection 2014.


Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.

Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM.

Cancer Cell Int. 2014 Jan 14;14(1):4. doi: 10.1186/1475-2867-14-4.


Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.

Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM.

PLoS One. 2013 Aug 6;8(8):e69748. doi: 10.1371/journal.pone.0069748. Print 2013.


Advances in therapy for melanoma brain metastases.

Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM.

Clin Dermatol. 2013 May-Jun;31(3):264-81. doi: 10.1016/j.clindermatol.2012.08.008. Review.


Studies of NVP-BEZ235 in melanoma.

Sznol JA, Jilaveanu LB, Kluger HM.

Curr Cancer Drug Targets. 2013 Feb;13(2):165-74. Review.


CD70 expression patterns in renal cell carcinoma.

Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL.

Hum Pathol. 2012 Sep;43(9):1394-9. doi: 10.1016/j.humpath.2011.10.014. Epub 2012 Mar 7.


Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.

Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.

PLoS One. 2012;7(2):e31331. doi: 10.1371/journal.pone.0031331. Epub 2012 Feb 15.


Melanoma brain metastases: is it time to reassess the bias?

Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, Knisely JP, Chiang VL, Kluger HM.

Curr Probl Cancer. 2011 Jul-Aug;35(4):200-10. doi: 10.1016/j.currproblcancer.2011.07.003. No abstract available.


A phase 2 trial of dasatinib in advanced melanoma.

Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M.

Cancer. 2011 May 15;117(10):2202-8. doi: 10.1002/cncr.25766. Epub 2010 Nov 29.


In vitro studies of dasatinib, its targets and predictors of sensitivity.

Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM.

Pigment Cell Melanoma Res. 2011 Apr;24(2):386-9. doi: 10.1111/j.1755-148X.2011.00835.x. No abstract available.


Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.

Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM.

Clin Cancer Res. 2010 Dec 15;16(24):6029-39. doi: 10.1158/1078-0432.CCR-10-1490.


Chemotherapy and biologic therapies for melanoma: do they work?

Jilaveanu LB, Aziz SA, Kluger HM.

Clin Dermatol. 2009 Nov-Dec;27(6):614-25. doi: 10.1016/j.clindermatol.2008.09.020. Review.


C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.

Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM.

Clin Cancer Res. 2009 Sep 15;15(18):5704-13. doi: 10.1158/1078-0432.CCR-09-0198. Epub 2009 Sep 8.


Dimeric SecA is essential for protein translocation.

Jilaveanu LB, Zito CR, Oliver D.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7511-6. Epub 2005 May 16.

Supplemental Content

Loading ...
Support Center